Thyroid Associated Ophthalmopathy Clinical Trial
Official title:
Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks: A Phase II Randomized Controlled Trial (OraGO-1 Trial)
Thyroid ophthalmopathy, also known as thyroid eye disease or Graves' ophthalmopathy, is a condition characterized by inflammation and swelling of the tissues around the eyes, often accompanied by protrusion of the eyeballs. This condition can lead to significant discomfort, visual disturbances, and in severe cases, permanent vision loss. Primary treatment modalities are intravenous methylprednisolone (IVMP) and other medications for patients with moderate to severe and active thyroid eye disease. In addition, external beam radiation therapy (ERT) is an another treatment option in combination with IVMP. Radiation therapy delivers targeted doses of ionizing radiation to the affected orbital tissues, effectively reducing inflammation. This approach is particularly beneficial for patients who may not respond adequately to steroid therapy alone or those who experience recurrent disease flares. This study will test the efficacy of a shortened treatment regimen comprising 5 sessions of ERT to a standard protocol of 10 treatments. The primary aim is to ascertain the effectiveness of shorted radiation treatment while improving patients' quality of life.
The research methodology of this study involves comparing the standard protocol of 10 radiation treatments with a modified approach comprising 5 treatments of daily External Beam Radiation Therapy (ERT). The primary objective of this investigation is to assess whether reducing the number of radiation treatments while maintaining the effectiveness of the therapy can lead to improvements in the quality of life for patients with thyroid ophthalmopathy. By comparing these two treatment regimens, researchers aim to evaluate the efficacy and safety of the abbreviated radiation schedule in managing the symptoms and progression of the disease. Participants enrolled in the study will be randomized into two groups: one receiving the standard 10 treatments and the other receiving the modified 5-treatment regimen of daily ERT. Throughout the study period, participants will undergo comprehensive assessments to monitor changes in symptoms, vision, and quality of life. These evaluations will include ophthalmic examinations, imaging studies, and patient-reported outcome measures to capture both objective and subjective measures of treatment response. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT06087731 -
Efficacy and Safety of Tocilizumab for TAO
|
Phase 2 | |
| Recruiting |
NCT05110040 -
Multi-model Image of Immunosuppressive Agents in TAO
|
N/A | |
| Recruiting |
NCT06112340 -
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03107078 -
Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial
|
Phase 4 | |
| Recruiting |
NCT04548284 -
Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO
|
Phase 3 | |
| Recruiting |
NCT03515863 -
Natural History and Risk Factors of TAO
|
||
| Recruiting |
NCT06226545 -
A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
|
Phase 2 | |
| Completed |
NCT00150111 -
Rituximab in the Treatment of Graves' Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT03110848 -
Effects of Atorvastatin in Graves' Orbitopathy (GO)
|
Phase 2 | |
| Recruiting |
NCT04662190 -
Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery.
|
N/A | |
| Active, not recruiting |
NCT05276063 -
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT04919694 -
Combination of Orbital Compression Surgery and Strabismus Surgery for Thyroid Associated Ophthalmopathy
|
N/A | |
| Recruiting |
NCT03131726 -
Treatment of Graves´Ophthalmopathy With Simvastatin (GO-S)
|
Phase 3 | |
| Completed |
NCT02766660 -
Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy
|
N/A | |
| Active, not recruiting |
NCT06269393 -
A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy
|
Phase 3 | |
| Not yet recruiting |
NCT03098225 -
A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy
|
Phase 4 | |
| Recruiting |
NCT05112211 -
Multi-model Image of Doxycycline in TAO
|
N/A |